An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations. Boumelha J, de Carne Trecesson S, Law EK, Romero-Clavijo P, et al. Cancer Res 2022 Aug 5. pii: 707449. doi: 10.1158/0008-5472.CAN-22-0325.

Read + Share

Amedeo Smart

Independent Medical Education

Boumelha J, de Carne Trecesson S, Law EK, Romero-Clavijo P, et al. An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations. Cancer Res 2022 Aug 5. pii: 707449. doi: 10.1158/0008-5472.CAN-22-0325.
PMID: 35930804